How much revenue did Imugene generate this year?
Imugene has achieved a revenue of 5.39 M AUD this year.
Imugene Revenue 2024
Imugene Revenue
5.39 M AUD
Ticker
IMU.AX
ISIN
AU000000IMU9
WKN
891460
In 2024, Imugene's sales reached 5.39 M AUD, a -54.27% difference from the 11.78 M AUD sales recorded in the previous year.
The Imugene Revenue history
| YEAR | REVENUE (undefined AUD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 952.06 | 1,24 |
| 2028e | 622.65 | 1,89 |
| 2027e | 311.98 | 3,78 |
| 2026e | 37.12 | 31,73 |
| 2025e | 2.56 | 460,34 |
| 2024e | 5.39 | 218,67 |
| 2023 | 11.78 | 100,00 |
| 2022 | - | - |
| 2021 | - | - |
| 2020 | - | - |
| 2019 | - | - |
| 2018 | 1.94 | 608,75 |
| 2017 | 1.2 | 982,09 |
| 2016 | 1.56 | 753,07 |
| 2015 | 0.64 | 1844,43 |
| 2014 | 0.54 | 2181,48 |
| 2013 | 0.21 | 5609,52 |
| 2012 | 0.29 | 4062,07 |
| 2011 | 2.2 | 535,45 |
| 2010 | 0.36 | 3272,22 |
| 2009 | 3.25 | 362,46 |
| 2008 | 0.41 | 2873,17 |
| 2007 | 0.48 | 2454,17 |
| 2006 | 0.37 | 3183,78 |
| 2005 | 0.39 | 3020,51 |
| 2004 | 0.12 | 9816,67 |
Imugene Revenue, EBIT, Net Income AU000000IMU9 · 891460
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Imugene, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Imugene from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Imugene’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Imugene. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Imugene’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Imugene’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Imugene’s growth potential.
Imugene Revenue, Profit, and EBIT History
| Date | Imugene Revenue | Imugene EBIT | Imugene Net Income |
|---|---|---|---|
| 2029e | 952.06 M undefined | 817.7 M undefined | 431.75 M undefined |
| 2028e | 622.65 M undefined | 492.31 M undefined | 288.33 M undefined |
| 2027e | 311.98 M undefined | 185.49 M undefined | 144.16 M undefined |
| 2026e | 37.12 M undefined | -79.55 M undefined | -59.14 M undefined |
| 2025e | 2.56 M undefined | -114.65 M undefined | -96.11 M undefined |
| 2024e | 5.39 M undefined | -132.64 M undefined | -130.63 M undefined |
| 2023 | 11.78 M undefined | -39.55 M undefined | -37.91 M undefined |
| 2022 | 0 undefined | -37.7 M undefined | -37.87 M undefined |
| 2021 | 0 undefined | -18.43 M undefined | -18.46 M undefined |
| 2020 | 0 undefined | -10.74 M undefined | -10.51 M undefined |
| 2019 | 0 undefined | -8.26 M undefined | -7.78 M undefined |
| 2018 | 1.94 M undefined | -3.84 M undefined | -3.93 M undefined |
| 2017 | 1.2 M undefined | -2.49 M undefined | -2.51 M undefined |
| 2016 | 1.56 M undefined | -2.7 M undefined | -2.73 M undefined |
| 2015 | 638,680 undefined | -2.25 M undefined | -2.44 M undefined |
| 2014 | 540,000 undefined | -800,000 undefined | -2.12 M undefined |
| 2013 | 210,000 undefined | -1.53 M undefined | -1.56 M undefined |
| 2012 | 290,000 undefined | -1.11 M undefined | -3.13 M undefined |
| 2011 | 2.2 M undefined | 310,000 undefined | 420,000 undefined |
| 2010 | 360,000 undefined | -1.71 M undefined | -1.54 M undefined |
| 2009 | 3.25 M undefined | 250,000 undefined | 650,000 undefined |
| 2008 | 410,000 undefined | -2.15 M undefined | -1.91 M undefined |
| 2007 | 480,000 undefined | -2.56 M undefined | -2.3 M undefined |
| 2006 | 370,000 undefined | -2.44 M undefined | -2.19 M undefined |
| 2005 | 390,000 undefined | -2.12 M undefined | -1.79 M undefined |
| 2004 | 120,000 undefined | -2.31 M undefined | -2.12 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 120,000 AUD | -2.31 M AUD | -2.12 M AUD |
| 2005 | 390,000 AUD | -2.12 M AUD | -1.79 M AUD |
| 2006 | 370,000 AUD | -2.44 M AUD | -2.19 M AUD |
| 2007 | 480,000 AUD | -2.56 M AUD | -2.3 M AUD |
| 2008 | 410,000 AUD | -2.15 M AUD | -1.91 M AUD |
| 2009 | 3.25 M AUD | 250,000 AUD | 650,000 AUD |
| 2010 | 360,000 AUD | -1.71 M AUD | -1.54 M AUD |
| 2011 | 2.2 M AUD | 310,000 AUD | 420,000 AUD |
| 2012 | 290,000 AUD | -1.11 M AUD | -3.13 M AUD |
| 2013 | 210,000 AUD | -1.53 M AUD | -1.56 M AUD |
| 2014 | 540,000 AUD | -800,000 AUD | -2.12 M AUD |
| 2015 | 638,680 AUD | -2.25 M AUD | -2.44 M AUD |
| 2016 | 1.56 M AUD | -2.7 M AUD | -2.73 M AUD |
| 2017 | 1.2 M AUD | -2.49 M AUD | -2.51 M AUD |
| 2018 | 1.94 M AUD | -3.84 M AUD | -3.93 M AUD |
| 2019 | 0 AUD | -8.26 M AUD | -7.78 M AUD |
| 2020 | 0 AUD | -10.74 M AUD | -10.51 M AUD |
| 2021 | 0 AUD | -18.43 M AUD | -18.46 M AUD |
| 2022 | 0 AUD | -37.7 M AUD | -37.87 M AUD |
| 2023 | 11.78 M AUD | -39.55 M AUD | -37.91 M AUD |
| 2024e | 5.39 M AUD | -132.64 M AUD | -130.63 M AUD |
| 2025e | 2.56 M AUD | -114.65 M AUD | -96.11 M AUD |
| 2026e | 37.12 M AUD | -79.55 M AUD | -59.14 M AUD |
| 2027e | 311.98 M AUD | 185.49 M AUD | 144.16 M AUD |
| 2028e | 622.65 M AUD | 492.31 M AUD | 288.33 M AUD |
| 2029e | 952.06 M AUD | 817.7 M AUD | 431.75 M AUD |
Imugene stock margins AU000000IMU9 · 891460
The Imugene margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Imugene. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Imugene.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Imugene's sales revenue. A higher gross margin percentage indicates that the Imugene retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Imugene's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Imugene's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Imugene's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Imugene. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Imugene's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Imugene Margin History
| Imugene Gross margin | Imugene Profit margin | Imugene EBIT margin | Imugene Profit margin |
|---|---|---|---|
| 2029e | 100 % | 85.89 % | 45.35 % |
| 2028e | 100 % | 79.07 % | 46.31 % |
| 2027e | 100 % | 59.46 % | 46.21 % |
| 2026e | 100 % | -214.28 % | -159.32 % |
| 2025e | 100 % | -4,480.17 % | -3,755.73 % |
| 2024e | 100 % | -2,462.18 % | -2,424.99 % |
| 2023 | 100 % | -335.71 % | -321.82 % |
| 2022 | 100 % | 0 % | 0 % |
| 2021 | 100 % | 0 % | 0 % |
| 2020 | 100 % | 0 % | 0 % |
| 2019 | 100 % | 0 % | 0 % |
| 2018 | 100 % | -198.58 % | -203.28 % |
| 2017 | 100 % | -207.21 % | -208.97 % |
| 2016 | 100 % | -172.9 % | -174.56 % |
| 2015 | 100 % | -351.65 % | -382.16 % |
| 2014 | 100 % | -148.15 % | -392.59 % |
| 2013 | 100 % | -728.57 % | -742.86 % |
| 2012 | 100 % | -382.76 % | -1,079.31 % |
| 2011 | 100 % | 14.09 % | 19.09 % |
| 2010 | 100 % | -475 % | -427.78 % |
| 2009 | 100 % | 7.69 % | 20 % |
| 2008 | 100 % | -524.39 % | -465.85 % |
| 2007 | 100 % | -533.33 % | -479.17 % |
| 2006 | 100 % | -659.46 % | -591.89 % |
| 2005 | 100 % | -543.59 % | -458.97 % |
| 2004 | 100 % | -1,925 % | -1,766.67 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 100 % | -1,925 % | -1,766.67 % |
| 2005 | 100 % | -543.59 % | -458.97 % |
| 2006 | 100 % | -659.46 % | -591.89 % |
| 2007 | 100 % | -533.33 % | -479.17 % |
| 2008 | 100 % | -524.39 % | -465.85 % |
| 2009 | 100 % | 7.69 % | 20 % |
| 2010 | 100 % | -475 % | -427.78 % |
| 2011 | 100 % | 14.09 % | 19.09 % |
| 2012 | 100 % | -382.76 % | -1,079.31 % |
| 2013 | 100 % | -728.57 % | -742.86 % |
| 2014 | 100 % | -148.15 % | -392.59 % |
| 2015 | 100 % | -351.65 % | -382.16 % |
| 2016 | 100 % | -172.9 % | -174.56 % |
| 2017 | 100 % | -207.21 % | -208.97 % |
| 2018 | 100 % | -198.58 % | -203.28 % |
| 2019 | 100 % | 0 % | 0 % |
| 2020 | 100 % | 0 % | 0 % |
| 2021 | 100 % | 0 % | 0 % |
| 2022 | 100 % | 0 % | 0 % |
| 2023 | 100 % | -335.71 % | -321.82 % |
| 2024e | 100 % | -2,462.18 % | -2,424.99 % |
| 2025e | 100 % | -4,480.17 % | -3,755.73 % |
| 2026e | 100 % | -214.28 % | -159.32 % |
| 2027e | 100 % | 59.46 % | 46.21 % |
| 2028e | 100 % | 79.07 % | 46.31 % |
| 2029e | 100 % | 85.89 % | 45.35 % |
Imugene Aktienanalyse
What does Imugene do?
Imugene Ltd is an Australian biotechnology company focused on the development of immunotherapies for various diseases, including cancer and infectious diseases. The company was founded in 2014 and is headquartered in Sydney. Imugene's business model is based on collaboration with academic institutions and other biotechnology companies to identify and develop promising drug candidates. The company also works closely with clinical researchers and physicians to accelerate drug development and ensure they meet patient needs. Imugene specializes in four different areas: oncology, immunology, infectious diseases, and neuroscience. Each area focuses on the development of drugs for specific diseases and medical needs. In the field of oncology, Imugene is focused on developing immunotherapy products for the treatment of breast cancer, colon cancer, lung cancer, and other types of cancer. Immunotherapy aims to strengthen the body's immune system to better destroy cancer cells. In the field of immunology, Imugene is focused on developing immunotherapy products for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Immunotherapy aims to modulate the immune system to eliminate disease-causing cells. In the field of infectious diseases, Imugene is focused on developing vaccines and products for the treatment of diseases such as COVID-19, influenza, hepatitis B, and HPV. Vaccines aim to activate the immune system to recognize and destroy pathogens before they can cause harm in the body. In the field of neuroscience, Imugene is focused on developing drugs for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's. These drugs aim to stimulate the brain's neuroprotective mechanisms to reduce nerve damage. Imugene has several promising products in the pipeline that aim to demonstrate the efficacy and safety of immunotherapy and other therapies. The company has already conducted clinical trials for some of these products, while others are still in preclinical development. One of Imugene's key products is HER-Vaxx, a vaccine for the treatment of breast cancer that activates the body's immune system against the HER2 protein, which promotes cancer growth in some individuals. The vaccine has been tested in clinical trials and has shown promising results. Another promising product from Imugene is PD1-Vaxx, a vaccine for the treatment of lung cancer that targets the activation of an important immune cell sensor. Preliminary study results suggest that treatment with PD1-Vaxx is synergistic with checkpoint inhibitors, another type of cancer treatment medication. Imugene is also working on a range of products for the treatment of COVID-19, including IMM-013, a vaccine against SARS-CoV-2, and IMM-036, an antibody against the virus. These products are being tested in preclinical development and are aimed at helping to contain the spread of the pandemic. Overall, Imugene aims to develop innovative drugs for the treatment of various medical needs. The company relies on close collaboration with academic and clinical partners to accelerate drug development and ensure its products meet the highest standards of efficacy and safety. Imugene ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Imugene's Sales Figures
The sales figures of Imugene originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Imugene’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Imugene's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Imugene’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Imugene Stock
How much was the turnover of the company Imugene compared to the previous year?
The revenue of Imugene has increased by -54.27% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Imugene?
The revenue of Imugene is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Imugene measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Imugene so important for investors?
The revenue of Imugene is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Imugene pay?
Over the past 12 months, Imugene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Imugene is expected to pay a dividend of 0 AUD.
What is the dividend yield of Imugene?
The current dividend yield of Imugene is .
When does Imugene pay dividends?
Imugene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Imugene?
Imugene paid dividends every year for the past 0 years.
What is the dividend of Imugene?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Imugene located?
Imugene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Imugene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Imugene from 6/24/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/24/2024.
When did Imugene pay the last dividend?
The last dividend was paid out on 6/24/2024.
What was the dividend of Imugene in the year 2023?
In the year 2023, Imugene distributed 0 AUD as dividends.
In which currency does Imugene pay out the dividend?
The dividends of Imugene are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Imugene
Our stock analysis for Imugene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Imugene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
